Bayer looks to have an edge over an established rival with elinzanetant, its soon-to-be-filed drug for menopause-related hot flashes, with full data readouts from two Phase III studies bolstering its profile. However, investors remain skeptical about its purported blockbuster prospects.
Elinzanetant is one of a few late-stage drugs that Bayer is relying on to help stabilize its pharma division sales...